Pathological complete response of locally advanced gastric cancer after four courses of neoadjuvant chemotherapy with paclitaxel plus cisplatin: Report of a case

Surgery Today

Volumn 42, Issue 10, 2012, Pages 983-987

  Watanabe, Takafumi ^a   Yoshikawa, Takaki ^a   Kameda, Yoichi ^a   Aoyama, Toru ^a   Hayashi, Tsutomu ^a   Ogata, Takashi ^a   Cho, Haruhiko ^a   Tsuburaya, Akira ^a   Morita, Satoshi ^b   Miyashita, Yumi ^c   Sakamoto, Junichi ^d  

^a Kanagawa Cancer Center   (Japan)

^b YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^c Nonprofit Organization ECRIN   (Japan)

^d NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Gastric cancer; Neoadjuvant chemotherapy; Pathological CR

Indexed keywords

CISPLATIN; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; PACLITAXEL;

ADULT; ADVANCED CANCER; ALOPECIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER INVASION; CANCER STAGING; CASE REPORT; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG RESPONSE; ESOPHAGUS METASTASIS; HUMAN; LYMPHADENOPATHY; MALE; MICROSCOPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; PANCREAS RESECTION; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SPLENECTOMY; STOMACH CANCER; TOTAL STOMACH RESECTION; TUMOR BIOPSY; TUMOR CELL;

ADENOCARCINOMA; ADULT; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; GASTRECTOMY; HUMANS; MALE; NEOADJUVANT THERAPY; PACLITAXEL; PANCREATECTOMY; SPLENECTOMY; STOMACH NEOPLASMS;

EID: 84867980826     PISSN: 09411291     EISSN: 14362813     Source Type: Journal    
DOI: 10.1007/s00595-012-0155-3     Document Type: Article

References (19)

1. Sasako M. Principles of surgical treatment for curable gastric cancer. J Clin Oncol. 2003;21:274-5.
2. Díaz de Liaño A, Yarnoz C, Aguilar R, Artieda C, Ortiz H. Rationale for gastrectomy with D2 lymphadenectomy in the treatment of gastric cancer. Gastric Cancer. 2008;11:96-102. (Pubitemid 351931667)
3. Ott K, Lordick F, Hermann K, Krause B-J, Schuhmacher C, Siewert Jr. The new credo: induction chemotherapy in locally advanced gastric cancer: consequences for surgical strategies. Gastric Cancer. 2008;11:1-9. (Pubitemid 351464481)
4. Cunningham D, Allum WH, Stenning SP, Thompson JN, van de Velde CJH, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11-20.
5. Fujii M, Kochi M, Takayama T. Recent advances in chemotherapy for advanced gastric cancer in Japan. Surg Today. 2010;40(4):295-300.
6. Yoshikawa T, Sasako M, Yamamoto S, Sano T, Imamura H, Fujitani K. Phase II study of neoadjuvant chemotherapy and extended surgery for locally advanced gastric cancer. Br J Surg. 2009;96(9):1015-22.
7. Yoshikawa T, Omura K, Kobayashi O, Nishimoto A, Takabayashi A, Yamada T, et al. A phase II study of preoperative chemotherapy with S-1 plus cisplatin followed by D2/D3 gastrectomy for clinically serosa-positive gastric cancer (JACCRO GC-01 study). Eur J Surg Oncol. 2010;36:546-51.
8. Baba H, Yamamoto M, Endo K, Ikeda Y, Toh Y, Kohnoe S, et al. Clinical efficacy of S-1 combined with cisplatin for advanced gastric cancer. Gastric Cancer. 2003;6:45-9. (Pubitemid 36604656)
9. Satoh S, Hasegawa S, Ozaki N, Okabe H, Watanabe G, Nagayama S, et al. Retrospective analysis of 45 consecutive patients with advanced gastric cancer treated with neoadjuvant chemotherapy using an S-1/CDDP combination. Gastric Cancer. 2006;9:129-35. (Pubitemid 43885771)
10. Sakurai K, Yamashita Y, Shimizu S, Yoshida K, FDukuoka T, Xiang Z, et al. A case of advanced gastric cancer responding to S-1 chemotherapy for three weeks. Jpn J Cancer Chemother. 2010;37:315-8.
11. Mori S, Kishimoto H, Tauchi K, Higuchi K. Histological complete response in advanced gastric cancer after 2 weeks of S-1 administration as neoadjuvant chemotherapy. Gastric Cancer. 2006;9:136-9. (Pubitemid 43885772)
12. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma, 2nd English edition. Gastric Cancer. 1998;1: 10-24.
13. Nagata N, Kimura M, Hirabayashi N, Tsuburaya A, Murata T, Kondo K, et al. Phase II study of weekly paclitaxel and cisplatin combination therapy for advanced or recurrent gastric cancer. Hepatogastroenterology. 2008;55:1846-50.
14. Yoshikawa T, Tsuburaya A, Morita S, Kodera Y, Ito S, Cho H, et al. A comparison of multimodality treatment: two or four courses of paclitaxel plus cisplatin or S-1 plus cisplatin followed by surgery for locally advanced gastric cancer, a randomized Phase II trial (COMPASS). Jpn J Clin Oncol. 2010;40:369-72.
15. Kinoshita T, Sasako M, Sano T, Katai H, Furukawa H, Tsuburaya A, et al. Phase II trial of S-1 for neoadjuvant chemotherapy against scirrhous gastric cancer (JCOG0002). Gastric Cancer. 2009;12:37-42.
16. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9:215-21.
17. Sakamoto J, Matsui T, Kodera Y. Paclitaxel chemotherapy for the treatment of gastric cancer. Gastric Cancer. 2009;12:69-78.
18. Koizumi W, Tanabe S, Saigenji K, Ohtsu A, Boku N, Nagashima F, et al. Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br J Cancer. 2003;89:2207-12. (Pubitemid 38168001)
19. Boku N, Yamamoto S, Fukuda H, Shirao K, Doi T, Sawaki A, et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol. 2009;10:1063-9.